New research reveals that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who halt traditional diet and exercise plans.
Research printed in a prominent health publication points out that while overweight individuals can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Individuals purchasing these medications must be informed of the potential of rapid rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to starting weight within about one and a half years.
Comparing Approaches
The study, which examined dozens of trials involving over 9,000 of participants, compared the results of the injectable medications with other pills.
The team note that people who lose weight through dieting typically see a slower weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors propose the mechanism of the jabs is key to understanding the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
The NHS advise the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, due to the likelihood of relapse, the therapy should be considered ongoing.
This view is echoed by drug manufacturers, who state that the results "underscore the long-term nature of excess weight," similar to managing conditions like hypertension.
User Accounts
Users who have come off the medication report a intense resurgence of cravings.
"I experienced a trigger flipping and you're instantly extremely hungry," described one woman.
The struggle is exacerbated if patients have not developed sustainable lifestyle or habit changes during therapy.
Widespread Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while these medications are effective agents for weight loss, they are not a magic cure and long-term success relies on integrated behavioural management.
